What's Happening?
Avenacy, a U.S.-based specialty pharmaceutical company, has announced the launch of its ready-to-use Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. This product is designed for short-term use in patients with hemophilia to reduce
or prevent hemorrhage and decrease the need for replacement therapy during and after tooth extraction. Each vial contains 1,000 mg per 100 mL and is available in cartons of 10 single-dose vials. The launch marks Avenacy's 27th product introduction since its inception in October 2023. The company emphasizes that this ready-to-use format will help healthcare providers deliver safe and efficient care by reducing preparation time and potential medication errors.
Why It's Important?
The introduction of this ready-to-use Tranexamic Acid injection is significant for the U.S. healthcare system, particularly for hospitals and clinics that manage hemophilia patients. By offering a product that reduces preparation time and potential errors, Avenacy is addressing critical needs in patient safety and care efficiency. The product's availability supports the dynamic drug supply chain, ensuring that essential medications are accessible and reliable. This launch also reflects Avenacy's commitment to expanding its portfolio of FDA-approved injectable products, reinforcing its position as a trusted partner in the pharmaceutical industry.
What's Next?
Avenacy plans to begin shipping the Tranexamic Acid injection to wholesale partners this week. The company is supported by a global network of development and contract manufacturing partners that comply with FDA cGMP standards. As the product enters the market, it is expected to capture a significant share of the $30.2 million U.S. sales of Tranexamic Acid Injection, particularly in the ready-to-use segment, which accounts for approximately $15 million of total sales.
